Navigation Links
Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimer's Disease From Merck
Date:12/21/2011

SAN FRANCISCO, Dec. 21, 2011 /PRNewswire/ -- Acumen Pharmaceuticals announces today the termination by Merck Sharp & Dohme Corp., (formerly Merck & Co., Inc.) of a 2003 agreement, amended in 2006, under which Acumen granted Merck exclusive worldwide rights to develop and commercialize anti-ADDL antibody therapeutics and diagnostics for Alzheimer's disease.

Merck's decision to discontinue this anti-ADDL Alzheimer's program and terminate the Merck-Acumen license agreement was based on internal strategic priorities. Under the termination provisions of the agreement, Acumen regains rights licensed to Merck, and also receives certain rights to patent applications and know how generated during the term of the Agreement. Anti-ADDL antibodies have high selectivity for soluble amyloid beta oligomers versus monomeric amyloid beta peptides or insoluble amyloid beta aggregates. Acumen believes this selectivity will favorably differentiate Acumen anti- ADDL immunotherapies compared to amyloid beta immunotherapies currently in late stage clinical testing.

"Acumen is very pleased to regain worldwide rights for the development and commercialization of anti-ADDL antibody therapeutics and diagnostics," stated Grant Krafft, Acumen's Chairman and Chief Science Adviser.

Acumen's Board of Directors also announces the appointment of Franz Hefti, Ph.D. as Acumen's President and CEO. Dr. Hefti has served as a Director of Acumen since 2008 and has a distinguished record in drug development and biotechnology ventures. Dr. Hefti served as Chief Science Officer for Avid Radiopharmaceuticals, which Eli Lilly & Co. acquired in 2010 for its Alzheimer's imaging product, Amyvid™. Prior to Avid, Dr. Hefti was Executive Vice President of Drug Development for Rinat Neuroscience Corporation where he led preclinical and clinical drug development efforts for three antibody drug candidates. The success of these programs led to Pfizer's 2006 acquisition of Rinat.
'/>"/>

SOURCE Acumen Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
2. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
6. Access Pharmaceuticals Signs Agreement for CobaCyte® and CobOral® in RNAi Therapeutic Delivery
7. Radient Pharmaceuticals Announces Proxy Resolutions Approved at Special Meeting of Stockholders
8. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
9. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
10. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Credit Suisse Healthcare Conference on November 9, 2011
11. Optimer Pharmaceuticals to Present at 20th Annual Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... YORK , July 28, 2014  David ... ConvergeHEALTH by Deloitte , has been elected ... Interchange Standards Consortium, a non-profit working to establish ... data, particularly as it relates to electronic health ... continue CDISC,s mission of collaborating with organizations across ...
(Date:7/28/2014)... July 28, 2014 It’s a hard truth: ... benefits to further their post-secondary education are failing to obtain ... released this year. And according to an analysis by ... is veteran students’ uninformed choice of college majors, which leads ... of the study: Some 51.7 percent of post-9/11 veterans using ...
(Date:7/28/2014)... DUBLIN , July 28, 2014 Research ... "Global Particle Size Analysis Market 2014-2018" report to their ... Particle size analysis is a technique used to determine ... powder or liquid. It is crucial to analyze the size ... material. Therefore, particle size analysis is performed to determine the ...
(Date:7/25/2014)... 25, 2014 Amgen (NASDAQ: AMGN ... a $0.61 per share dividend for the third quarter ... 5, 2014, to all stockholders of record as of ... About Amgen Amgen is committed to unlocking ... illnesses by discovering, developing, manufacturing and delivering innovative human ...
Breaking Biology Technology:ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 4Global Particle Size Analysis Market 2014-2018 2Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3
... today announced the receipt of a two-year Small Business ... the National Institute on Aging, National Institutes of Health ... antibodies targeting tau protein oligomers in the development of ... be screened at the Michigan High Throughput Screening Center ...
... Wound Management Technologies, Inc., (OTC Bulletin Board: ... solutions, announced today that its President, Deborah Jenkins Hutchinson, ... product, CellerateRX®, recent strategic developments, and its product pipeline ... be held at the JW Marriott Marquis Miami on ...
... a way to overcome one of the main limitations of ... Everyone who has had an ultrasound, including most pregnant women, ... of the limits to the detail obtainable with sonography is ... dictate that the smallest objects you can "see" are about ...
Cached Biology Technology:Oligomerix, Inc. Awarded Phase II NIH Grant to Discover Novel Drugs for Alzheimer's Disease 2Wound Management Technologies to Present at LifeTech Capital Miami Medical Investors Conference 2Novel metamaterial vastly improves quality of ultrasound imaging 2
(Date:7/27/2014)... In one of the largest prevalence studies to date, ... genotype prevalence estimates for the hepatitis C virus (HCV). ... Association for the Study of Liver Diseases, indicate that ... 83 million patients infected of which one-third reside in ... cases, is the next most prevalent, followed by genotypes ...
(Date:7/27/2014)... RESEARCH UK scientists at Barts Cancer Institute have found ... cancer therapy significantly more effective, according to research published ... Barts Cancer Institute, part of Queen Mary University of ... kinase (FAK), signals the body to repair itself after ... DNA. When the researchers removed FAK from blood vessels ...
(Date:7/25/2014)... Before the colonial era, 100,000s of people lived on ... cultures manipulated fire to control the availability of plants ... tribes continue to use fire to maintain desired habitat ... the U.S. Forest Service,s Pacific Southwest Station, will lead ... National Wildfire Refuge during the Ecological Society of America,s ...
Breaking Biology News(10 mins):Hepatitis C virus genotype 1 is most prevalent worldwide 2New drug target can break down cancer's barrier against treatment 2Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3
... the University of Maryland Center for Environmental Science ... a lack of predators and competitors was the ... dogfish observed in Southern New Englands Georges Bank ... 1980s. In an article appearing in the ...
... a new environment while others do not" Scientists from ... headway on this question after analyzing how fast cane ... 70 years of data on toad presences collected since ... regions of Australia at dramatically divergent rates. These variable ...
... Arenas, Chile, on the tip of South America, to spend ... Southern Ocean. Here they hope to make groundbreaking measurements to ... and sea, and vice-versa. The cruise, ... the greenhouse gas carbon dioxide moves between the ocean and ...
Cached Biology News:Researchers offer new theory for dogfish and skate population outburst on George's Bank 2Voyage to Southern Ocean aims to study air-sea fluxes of greenhouse gases 2